

**Drug Development Considerations for the Treatment of Congenital  
Cytomegalovirus Infection and Neonatal Enterovirus Infection —FDA Virtual  
Public Workshop—May 7-8, 2024**

**Speakers and Panelists: Affiliations and Disclosures**

**Mark Abzug, MD**

Professor of Pediatrics (Infectious Diseases)  
Vice Chair for Academic Affairs, Department of Pediatrics  
University of Colorado School of Medicine  
Aurora, CO

**Yodit Belew, MD**

Associate Director, Therapeutics  
Division of Antivirals (DAV)  
Office of New Drugs (OND), Office of Infectious Diseases (OID)  
Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA)  
Silver Spring, MD

**Tien Bo, PharmD**

Global Medical Unit Head  
Transplant and New Programs  
Takeda Pharmaceuticals  
Lexington, MA

**David Byron**

Head of Research and Development  
AntiVirus Therapeutics  
7 Ardsley Court  
Princeton Junction, NJ

**John Concato, MD, MS, MPH**

Associate Director, Real-World Evidence Analytics  
Office of Medical Policy, CDER  
FDA  
Silver Spring, MD

**Lindsay DeVries, Au.D., Ph.D.**

Scientific Reviewer  
Office of Product Evaluation and Quality (OPEQ)  
Center for Devices and Radiological Health (CDRH)  
FDA  
Silver Spring, MD

**Roberta L. DeBiasi, MD, MS**

Chief, Division of Pediatric Infectious Diseases  
Robert H. Parrott Professor of Pediatric Research  
Children's National Hospital and Research Institute  
Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine  
The George Washington University School of Medicine  
Washington, DC

**Miranda Delahoy, PhD, MSPH**

Senior Epidemiologist  
Acute Flaccid Myelitis and Domestic Polio Team  
Polio and Picornavirus Branch, Division of Viral Diseases  
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention (CDC)  
Atlanta, GA

**Rachel G. Greenberg, MD, MB, MHS**

Associate Professor of Pediatrics, Division of Neonatology  
Duke University School of Medicine  
Duke Clinical Research Institute  
Durham, NC

**Paul Griffiths MD DSc FRCPath**

Emeritus Professor of Virology  
University College London

**Jeffrey Hincks, PhD**

Co-Founder, President  
ViroDefense, Inc.  
Chevy Chase, MD

**David W. Kimberlin, MD**

Professor and Vice Chair of Clinical and Translational Research  
Co-Director, Division of Pediatric Infectious Diseases  
University of Alabama at Birmingham  
Birmingham, AL

**Tatiana Lanzieri, MD, MPH**

Medical Epidemiologist  
CMV Program Lead  
Measles, Rubella, and Cytomegalovirus Epidemiology Team  
Viral Vaccine Preventable Diseases Branch / Division of Viral Diseases  
National Center for Immunization and Respiratory Diseases  
CDC  
Atlanta, GA

**Aimee Hodowanec, MD**

Medical Team Leader  
DAV, OID  
OND, CDER  
FDA  
Silver Spring, MD

**Ryan Kau, MD**

Medical Officer  
ENT Device Team  
Division Health Technology 1B/Office of Health Technology 1  
OPEQ, CDRH  
FDA  
Silver Spring, MD

**An N. Massaro, MD**

Supervisory Medical Officer  
Neonatology and Rare Pediatric Disease Team  
Office of Pediatric Therapeutics  
Office of Clinical Policy and Programs / Office of the Commissioner (OC)  
FDA  
Silver Spring, MD

**Kevin Messacar, MD PhD**

Associate Professor of Pediatrics  
Sections of Hospital Medicine and Pediatric Infectious Diseases  
University of Colorado, Children's Hospital Colorado  
Aurora, CO

**Emma Mohr, MD, PhD**

Assistant Professor  
Division of Infectious Diseases  
Department of Pediatrics  
University of Wisconsin-Madison  
Madison, WI

**Lily (Yeruk) Mulugeta, PharmD**

Associate Director, Policy and Research  
Division of Pediatric and Maternal Health  
OND, CDER  
FDA  
Silver Spring, MD

**M. Steven Oberste, PhD**

Director (Acting)  
Division of Viral Diseases  
National Center for Immunization and Respiratory Diseases, CDC  
Atlanta, GA

**Megan Honor Pesch, MD, MS**

Clinical Assistant Professor  
Director, Congenital CMV Follow-up Clinic  
Division of Developmental & Behavioral Pediatrics  
Department of Pediatrics  
University of Michigan / Michigan Medicine  
Ann Arbor, MI

**Natalie Pica, MD, PhD**

Senior Physician  
Associate Director for Pre-IND Services  
DAV, OID  
OND, CDER  
FDA  
Silver Spring, MD

**Betsy Pilon**

Executive Director  
Hope for Hypoxic Ischemic Encephalopathy (HIE)  
Detroit, MI

**Amy B Rosenfeld, PhD**

Principal Investigator  
Division of Viral Products  
Office of Vaccines Research and Review  
Center for Biologics Evaluation and Review (CBER)  
FDA  
Silver Spring, MD

**Mark R. Schleiss, MD**

American Legion and Auxiliary Heart Foundation Research Professor  
Department of Pediatrics  
University of Minnesota (UMN) Medical School  
Minneapolis, MN

**Prabha Viswanathan, MD**

Deputy Director  
Office of Pediatric Therapeutics, OC  
FDA  
Silver Spring, MD

**Matthew R. Vogt, MD, PhD**

Assistant Professor of Pediatrics and Microbiology & Immunology  
University of North Carolina at Chapel Hill School of Medicine  
Chapel Hill, NC

**Kunyi Wu, PharmD**

Clinical Pharmacology Team Leader  
Division of Infectious Disease Pharmacology (DIDP), Office of Clinical Pharmacology (OCP)  
Office of Translational Sciences (OTS), CDER  
FDA  
Silver Spring, MD

**Voluntary Disclosures**

**Dr. Abzug:** Receives grant support to his institution from the National Institutes of Health.

**Dr. Greenberg:** Receives grant support from the National Institutes of Health. She has received support from industry for research services (<https://dcri.org/about-us/conflict-of-interest/>).

**Dr. Griffiths:** Advisory Board consultancies for Takeda 2022, Evrys 2023, Moderna 2023. United Kingdom Patent Application No. 2020135.6 "Human CMV Vaccine" Assigned to University College London with PG as one named inventor.

**Dr. Kimberlin** Receives research support from the NIH for his role as Principal Investigator (PI) of the Congenital and Perinatal Infections Consortium (CPIC) within the NCATS Rare Diseases Clinical Research Network. He is editor of the American Academy of Pediatrics Red Book, and editor-in-chief of Long's Principles and Practice of Pediatric Infectious Diseases. He also is course director for the Infectious Diseases in Children Symposium in New York City each November. Within the past two years he was site PI for two pediatric studies of remdesivir sponsored by Gilead; all monies went directly to his university.

**Dr. Mohr:** Receives grant support from the National Institutes of Health.

**Dr. Schleiss:** Received research support from the NIH. He also receives research support, but no personal honoraria, as the UMN site PI of the Moderna CMV mRNA-1647 vaccine study.

**Dr. Vogt:** Is an inventor on a patent for anti-EV-D68 human monoclonal antibodies.